|Articles|December 1, 1996

Creating an Optimal Strategy for Lipid Management
Volume 2
Issue 11 Suppl

Case Study B

Author(s)Donald B. Hunninghake, MD, MyNgoc A. Dang, PharmD, Larry Goodnight, RPh

Download PDF: Case Study B

Articles in this issue

over 29 years ago

Article

Dialogue: Implementation of Guidelines in a Managed Care Setting

over 29 years ago

Article

Dialogue: The Lipid-Lowering Formulary

over 29 years ago

Article

Case Study C

over 29 years ago

Article

Case Study D

over 29 years ago

Article

Goals and Objectives

over 29 years ago

Article

Introduction: Creating an Optimal Strategy for Lipid Management

over 29 years ago

Article

Recent Clinical Trials and Aggressive Management of Dyslipidemic Patients

over 29 years ago

Article

Epidemiologic Studies of Diet and Drug Therapy to Reach Target LDL-C Levels

over 29 years ago

Article

Implementation of Guidelines in a Managed Care Setting

over 29 years ago

Article

The Lipid-Lowering Formulary

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Case Study B

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

5 Things to Know About Retatrutide, the "Trillion-Dollar" Drug

GLP-1 Use Remains Rare Among Eligible Patients With Multiple Sclerosis

Retina Specialists Favor Efficacy Over Risk in Geographic Atrophy Care

Sarcoma Gene Signature May Predict Who Benefits From Pazopanib

Lifestyle Factors Offer Actionable Targets in MASLD Management: Zobair M. Younossi, MD